PFE Stock Risk & Deep Value Analysis

Pfizer Inc

Healthcare • Drug Manufacturers - General

DVR Score

0.1

out of 10

Distressed

What You Need to Know About PFE Stock

We analyzed Pfizer Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PFE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated Mar 13, 2026•Run Fresh Analysis →

How Risky Is PFE Stock?

Overall Risk

Moderate

Financial Risk

Low

Market Risk

Medium

Competitive Risk

High

Execution Risk

Medium

Regulatory Risk

High

What Are the Red Flags for PFE?

⚠
Patent expiry for major revenue-generating drugs (ongoing threat)
⚠
Clinical trial failures or significant delays for key pipeline assets
⚠
Increased regulatory scrutiny or pricing pressure on pharmaceutical drugs
⚠
Intensified competition in key therapeutic areas (e.g., oncology, immunology)

Unlock PFE Red Flags & Risk Warnings

Create a free account to see the full analysis

What Does Pfizer Inc (PFE) Do?

Market Cap

$140.30B

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

81,000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Visit Pfizer Inc Website

Is PFE Stock Undervalued?

Pfizer Inc. is a mature, large-cap pharmaceutical company with a market capitalization of $152.73B. While it possesses significant R&D capabilities, a global distribution network, and a diversified pipeline (enhanced by the Seagen acquisition), its inherent size and the established nature of the pharmaceutical industry make 10x growth within 3-5 years highly improbable. Such growth would imply a market cap exceeding $1.5 trillion, a level typically reserved for global tech giants, not a pharmaceutical company facing ongoing patent cliffs and integration challenges. The business model, while scalable for individual drugs, is not designed for the exponential, sector-defining growth across its entire portfolio needed to justify a 10x return in this timeframe. Despite strategic pivots and strong leadership, the fundamental market dynamics and competitive landscape do not support this level of accelerated valuation. Therefore, it does not qualify for 10x growth potential.

Unlock the full AI analysis for PFE

Get the complete DVR score, risk analysis, and more

Is PFE Financially Healthy?

P/E Ratio

13.06

Does PFE Have a Competitive Moat?

Moat Rating

🏰 Wide

Moat Trend

Stable

Moat Sources

4 Identified

Intangible Assets/IP (patents, regulatory approvals, proprietary research)Brand Power (reputation, physician trust)Cost Advantages (scale in manufacturing, distribution, and R&D efficiencies)Switching Costs (for certain chronic or critical care treatments)

Pfizer's moat is durable due to the high costs, long development cycles, and stringent regulatory hurdles inherent in the pharmaceutical industry. Its vast intellectual property portfolio and global reach protect its market position, though continuous innovation is required.

Moat Erosion Risks

•Significant patent expirations (patent cliffs) leading to revenue erosion
•Failure of key pipeline drugs to gain regulatory approval or market acceptance
•Increased competition from biosimilars and generics
•Disruptive innovation from smaller, agile biotech firms

PFE Competitive Moat Analysis

What Could Drive PFE Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (estimated early May 2026)
•Updates on Seagen integration and oncology pipeline progress (Q2 2026)
•Potential PDUFA dates for new drug indications or novel therapies (e.g., late 2026)

Medium-Term (6-18 months)

•Phase 3 clinical trial readouts for key pipeline assets (2026-2027)
•Expanded market penetration for recently launched products (e.g., RSV vaccine, Seagen's oncology drugs)
•Strategic partnerships or bolt-on acquisitions to bolster pipeline

Long-Term (18+ months)

•Development and commercialization of next-generation mRNA technologies beyond infectious diseases (2028+)
•Evolution of oncology portfolio to become a dominant revenue driver post-Seagen (2028+)
•Leveraging AI and data analytics in drug discovery and development to accelerate timelines

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for PFE?

✓
Successful integration and synergy realization from the Seagen acquisition
✓
Positive clinical trial results for late-stage pipeline assets and subsequent regulatory approvals
✓
Management of patent cliffs and successful revenue replacement from new product launches
✓
Consistent dividend growth and share buyback programs

Bull Case Analysis

See what could go right with Premium

Compare PFE to Similar Stocks

See how Pfizer Inc stacks up against related companies in our head-to-head analysis.

PFE vs JNJ

Compare →

PFE vs XLV

Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PFE (Pfizer Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.